Frontiers in Molecular Neuroscience-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2023-06-18 Asunaroy_2023 来自广东省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：疼痛;分子机制;肠道菌群
经验分享：版面费太贵了。。。。

35 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2023-06-18 ms3000001934068600 来自广东省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：疼痛;菌群组学;分子机制
经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。
只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。
各阶段时间参考：
30 May 2023 Article accepted for publication.
29 May 2023 Review of Review Editor 2 (大修) finalized.
25 May 2023 Review of Review Editor 1 (小修) finalized.
25 May 2023 Submitting Author posted new comments and re-submitted manuscript.
12 May 2023 Interactive review forum activated.
18 Apr 2023 Submitting Author submitted manuscript.

35 0

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2021-11-02 仁者神归

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：基础研究;精神疾病;神经疾病
经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！

80 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2021-07-13 12333

审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0
偏重的研究方向：疼痛;药物
经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。

63 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2017-04-14 lingyun_87

审稿速度:2.0
经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~

309 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2022-05-07 121c6f2dm84(暂无昵称)

投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的

52 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2021-12-29 衣谷

什么是推荐reviewer/专家/同行？

67 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2021-12-28 学医的彭于晏

上传文章时应该上传word还是pdf？

55 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2018-02-03 大亮亮

审稿速度:2.0 | 投稿命中率:25.0
经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。

420 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2143499, encodeId=fb972143499ca, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;分子机制;肠道菌群 经验分享：版面费太贵了。。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=Asunaroy_2023, createdTime=Sun Jun 18 14:34:13 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2143497, encodeId=d6d9214349e8e, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：疼痛;菌群组学;分子机制 经验分享：杂志效率还是很高的，编辑找了2个审稿人，一个小修，一个大修提了关于补实验的问题，给了2周时间修改+回复审稿人意见，没有补实验，只回复了两位审稿人的意见，两位审稿人直接endorse了。综合来看审稿人的意见大部分比较中肯。就是版面费太贵了。。。 只根据杂志要求提交了测序的原始数据，后续编辑部没有要分子实验（WB，IF，qPCR等）的原始数据。 各阶段时间参考： 30 May 2023 Article accepted for publication. 29 May 2023 Review of Review Editor 2 (大修) finalized. 25 May 2023 Review of Review Editor 1 (小修) finalized. 25 May 2023 Submitting Author posted new comments and re-submitted manuscript. 12 May 2023 Interactive review forum activated. 18 Apr 2023 Submitting Author submitted manuscript., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9d98249207, createdName=ms3000001934068600, createdTime=Sun Jun 18 14:30:09 CST 2023, time=2023-06-18, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=1066270, encodeId=099510662e083, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础研究;精神疾病;神经疾病 经验分享：在另两篇杂志拒稿后转投该杂志，审稿人相对友好。三周左右修回，小修后不到一周接受。人生第一篇，值得庆贺！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=80, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKGw6BqXfw6ziccqFNrFXpnkicNycjq0wpRumibkTzaOgXW0vEWVTFXibofUtnu8DViaIH6YWyU9WBevHw/132, createdBy=2db72344583, createdName=仁者神归, createdTime=Tue Nov 02 16:07:57 CST 2021, time=2021-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999156, encodeId=0b2a99915607, content=审稿速度:6.0 | 投稿命中率:25.0 | 版面费用:2900.0 偏重的研究方向：疼痛;药物 经验分享：投稿两天后分配编辑，编辑手里待了一个月后突然换一个编辑，然后拒稿。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=63, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=07015509193, createdName=12333, createdTime=Tue Jul 13 18:06:57 CST 2021, time=2021-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=535559, encodeId=047f5355599b, content=审稿速度:2.0 经验分享：修回意见已经3周了~审稿人2还是没有回复~急死了~~, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=309, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=71321647318, createdName=lingyun_87, createdTime=Fri Apr 14 09:42:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1217576, encodeId=a253121e57662, content=投了一篇生信，审稿2个月，3个月左右接收，frontiers还是相对比较好投的, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=52, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08542281224, createdName=121c6f2dm84(暂无昵称), createdTime=Sat May 07 10:44:46 CST 2022, time=2022-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106068, encodeId=73ce1106068b9, content=什么是推荐reviewer/专家/同行？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=67, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Wed Dec 29 14:52:52 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1106067, encodeId=9aec110606e10, content=上传文章时应该上传word还是pdf？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=81a55564862, createdName=学医的彭于晏, createdTime=Tue Dec 28 14:52:52 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=552305, encodeId=6ad2552305c8, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：审稿严格，第一次遇到4个评审的情况。两个评审比较友好，两个比较刁难。大修加小修共三个月，最后接收。互动审稿模式比较新颖，编辑与评审都很负责任。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=420, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e74c2044174, createdName=大亮亮, createdTime=Sat Feb 03 11:08:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590693, encodeId=3316590693b8, content=要的大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, beContent=大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a0755134054, createdName=14660d1em11暂无昵称, createdTime=Tue May 12 00:00:00 CST 2020, time=2020-05-12, status=1, ipAttribution=)]

2020-05-12 14660d1em11暂无昵称

要的大骨棒 2019-12-10 00:00:00 发表:
这个杂志好中嘛？会不会同行评审前先润色？

大骨棒 2019-12-10 00:00:00 发表: 这个杂志好中嘛？会不会同行评审前先润色？

159 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务